Leadership and operating model

Clinical research leadership grounded in execution

4Cs provides sponsor-side embedded oversight with documented governance, continuity controls, and clear interfaces across sponsor, CRO, vendor, medical, safety, and site teams.

Founder and principal

Ghassan Ahmed, MD, PMP, ACRP CCRA

Clinical operations, medical oversight, and research governance

Ghassan Ahmed, founder and principal of 4Cs

4Cs is led by Ghassan Ahmed, with more than 15 years of clinical research experience across sponsor, CRO, site, and medical monitoring environments. Experience spans oncology, dermatology, immunology, neurology, infectious disease, renal disease, diagnostics, and regional trial operations in the United States and MENA.

Areas of experience include clinical operations leadership, sponsor oversight, CRO governance, medical monitoring support, safety review governance, inspection readiness, protocol and informed-consent review, SOP development, and clinical research training.

Professional profile links, client names, and quantified client outcomes are published only when verified and approved. Relevant personnel qualifications and experience can be reviewed during qualification.

Public proof policy

Authority evidence without unsupported claims

4Cs publishes only verified authority signals: approved leadership profiles, confirmed credentials, controlled qualification materials, and permission-cleared client evidence.

Mission

Help clinical trial sponsors reduce operational and medical oversight risk through clear governance, disciplined review, and accountable collaboration.

Global and regional perspective

Leadership experience includes Phase I-IV oversight across multiple therapeutic areas, with particular experience supporting US and MENA operating environments.

Operating principles

  • Define ownership and decision rights
  • Document oversight and material decisions
  • Escalate through accountable closure
  • Keep governance proportionate to program risk

How 4Cs integrates

  • Works alongside sponsor and CRO partners
  • Uses agreed reporting and review cadence
  • Aligns response expectations to protocol and operating risk
  • Supports continuity during leadership transitions